[Skip to Content]
[Skip to Content Landing]
July 14, 1975

Dosage Errors With Heparin

Author Affiliations

The US Pharmacopeial Convention, Inc. Rockville, Md

JAMA. 1975;233(2):138. doi:10.1001/jama.1975.03260020024014

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  Physicians concerned about the content and format of labels on drug containers should be aware of the USP Drug Product Defect Reporting Program. Confusing labels or inadequately labeled products are reportable defects. Report forms are generally available in hospital and community pharmacies, or may be obtained by writing to these USP headquarters.Reports are sent to the USP, where copies are made for the manufacturer and for the Food and Drug Administration (FDA); for the FDA, the information is also codified into computer-processable form for trends analysis. The Drug Product Defect Reporting Program is funded by the FDA and conducted by the USP with the cooperation of national and state and local associations of pharmacy. The program is regularly cited by FDA officials as an important aspect of the government's quality assurance program and for its achievement of consistent input from concerned health care practitioners.Defects reported